WealthShield Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

WealthShield Partners’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-233	Closed	-$143K	–	342
2022 Q1	$143K	Hold	233	–	–	0.02%	325
2021 Q4	$142K	Buy	233 +67	+40%	+$63K	0.02%	276
2021 Q3	$162K	Buy	166 +75	+82%	+$93.8K	0.04%	229
2021 Q2	$135K	Buy	+91	New	+$198K	0.02%	318

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WealthShield Partners's APTO Position: Q2 2022 in Review

WealthShield Partners sold out of Aptose Biosciences, Inc. (APTO) in Q2 2022, closing a stake of 233 shares — an estimated $143K sold.

WealthShield Partners first reported a position in APTO in Q2 2021 and held it in 4 quarters. The position peaked at $162K in Q3 2021. 48 funds tracked by Wall St. Rank hold APTO as of Q2 2022.

WealthShield Partners reported no remaining Aptose Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
WealthShield Partners sold 233 Aptose Biosciences, Inc. shares in Q2 2022, an estimated $143K.
WealthShield Partners first reported a position in Aptose Biosciences, Inc. in Q2 2021 and held it in 4 quarters.
WealthShield Partners's Aptose Biosciences, Inc. position peaked at $162K in Q3 2021.
48 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2022.

Based on WealthShield Partners's 13F filing for Q2 2022, filed 11 Aug 2022.